Abstract
BackgroundEfonidipine hydrochloride (EFO) is a poorly water-soluble drug and, hence, has poor bioavailability. Solid dispersions (SDs) of EFO using Eudragit EPO were prepared using hot-melt extrusion (HME) for the first time. The current study aims at developing a simple RP-HPLC method to quantify EFO in the developed SDs.ResultsThe chromatographic separation was carried out on an Agilent Eclipsed XDB-C18 column (4.6 × 250 mm), packed with 5 μm particles. The optimized mobile phase consisted of HPLC grade acetonitrile and 0.020 mol/L KH2PO4 (pH 2.5) buffer in the ratio of 85:15 v/v with a flow rate optimized at 1.2 ml/min. The developed method was validated for system suitability, linearity, accuracy, precision, and robustness. The linearity results showed an excellent linear relationship between the drug concentration and peak area, indicating the peak area is directly proportional to the analyte concentration within a specific range and an excellent correlation coefficient of 0.9998. Intermediate precision and repeatability confirmed that the method provides precise results with %RSD value less than 2% for EFO. The assay results of the developed formulations were in the acceptable range with RSD less than 2%. The enhanced drug dissolution from the Eudragit EPO carrier with 10% Citric Acid (CA) is attributed to the conversion of the drug from crystalline to amorphous form, and microenvironmental acidic pH provided by CA.ConclusionIn a nutshell, the developed RP-HPLC method showed excellent ability to differentiate the formulations and highlights the role of the polymer and the plasticizer.Graphical abstract
Highlights
Efonidipine hydrochloride (EFO) is a poorly water-soluble drug and, has poor bioavailability
(2020) 6:70 method, we propose to develop and validate a simple, reliable, and accurate Reverse-phase high-performance liquid chromatography (RP-HPLC) method for the quantification of EFO and determine the drug release from the developed Solid dispersion (SD)
The solubility and dissolution rate of poorly soluble EFO was enhanced by the solid dispersion approach using hot-melt extrusion (HME)
Summary
Efonidipine hydrochloride (EFO) is a poorly water-soluble drug and, has poor bioavailability. The current study aims at developing a simple RP-HPLC method to quantify EFO in the developed SDs. Efonidipine hydrochloride (EFO) (Fig. 1) is a novel 1,4dihydropyridine derivative calcium channel antagonist. Efonidipine hydrochloride (EFO) (Fig. 1) is a novel 1,4dihydropyridine derivative calcium channel antagonist It is 2-(phenyl-(phenylmethyl) amino) ethyl 5-(5,5-dimethyl-2-oxo-1,3-dioxa-2λ5-phosphacyclohex2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3 carboxylate with empirical formula of C34H38N3O7P and molecular weight of 631.65. It is a pale yellowish powder with a melting range of 154.7 to 172.0 °C and a very high boiling point of 746.9 °C. The. A simple yet very promising approach to enhance the solubility of the drug is the preparation of amorphous solid dispersions. In the Rajput et al Future Journal of Pharmaceutical Sciences (2020) 6:70 method, we propose to develop and validate a simple, reliable, and accurate RP-HPLC method for the quantification of EFO and determine the drug release from the developed SDs
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
